We are happy to report that our research efforts are going well. As many of our shareholders know, ReceptoPharm’s main therapeutic focus is in the neurological (including pain) and antiviral areas.

Recent research highlights include:

• Confirming the activity of RPI-78M in animal models of the autoimmune disease Multiple sclerosis, in addition to identifying novel target genes through the use of micro-array studies, may suggest a broader activity by the drug than just as an immune suppressant. Reference to this work was recently published with the help of our collaborators at the MS Cameco Center in Saskatchewan. We are due to present more on this line of research at the 11th International Symposium on Immunobiology in Tahoe City in September.
• From our collaborative research efforts with Soochow University in China we have learned that the raw material for RPI-78M is a potent analgesic agent. We recently published that research also. Pain control is a major therapeutic area that is not well met. The use of such proteins in medicine is widely accepted in China and their reported success instills further motivation is us to continue this line of research.
• We are expecting to start our London based clinical trials by the year-end and on the back of that success we are moving forward with efforts to start clinical trials in patients with Multiple sclerosis here in the U.S. We will continue to update you on our efforts.

Paul

SEC Disclaimer
This article contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The above article, " Good News for ReceptoPharm Drug Discovery", should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

               

Comments

No comments yet.

RSS feed for comments on this post.

TrackBack URL

Leave a Comment

Name (required)

Email (will not be published) (required)

Website